InterMune Patents

Patent portfolio assigned to InterMune (verified via public assignee records). Biotech (IPF/pulmonology), maker of Esbriet/pirfenidone; acquired by Roche for $8.3B in 2014, now defunct. Primary therapeutic competitor was Boehringer Ingelheim's Ofev (nintedanib). Drug-development company with no commercial 'customers' in the usual sense. InterMune Inc. is a patent assignee (multiple pirfenidone patents, e.g. US8318780B2, US7767225B2; later reassigned to Legacy Pharma).